Maveropepimut-S

DB17339InvestigationalVaccines

Maveropepimut-S is a T cell activating immunotherapy.

Mechanism: Pharmacologically active on Baculoviral IAP repeat-containing protein 5
Curator reviewed
Also known as: DPX-Survivac · Maveropepimut S · MVP-S
Code names: EMD-640744

Resolves to

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Maveropepimut-S, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.